Luspatercept
Luspatercept 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为MDS、Myelodysplastic Syndromes。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
18 项
全球在招研究
1 项
已进入 III/IV 期
25 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Groupe Francophone des Myelodysplasies
- Yale University
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- National Cancer Institute (NCI)
- Celgene
- Bristol-Myers Squibb
- Associazione Qol-one
- Memorial Sloan Kettering Cancer Center
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、意大利、加拿大、Puerto Rico、澳大利亚、比利时、Bulgaria、中国、法国、德国、Greece、Israel
正在招募患者的 Luspatercept 研究
Luspatercept + Darbepoetin in MDS
II 期招募中美国NCT07096297Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
不适用招募中意大利NCT05931718MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
II 期招募中美国加拿大Puerto RicoNCT05564390A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
III 期招募中美国澳大利亚比利时BulgariaNCT04064060Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
II 期招募中美国中国德国GreeceNCT04143724A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia
不适用招募中South KoreaNCT06073860Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)
I 期招募中法国NCT06670222Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
I 期 / II 期招募中法国意大利NCT05181735Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD
II 期招募中意大利NCT05924100A Study of Luspatercept in People With Anemia
II 期招募中美国NCT07725497Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT)
I 期 / II 期招募中中国NCT07362095Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients
II 期招募中中国NCT07338344Luspatercept for CIA in AML
I 期 / II 期招募中中国NCT07663864Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
II 期招募中美国加拿大法国德国NCT06517875A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East
不适用招募中KuwaitOmanSaudi ArabiaUnited Arab EmiratesNCT07215975Luspatercept for Clonal Cytopenias of Uncertain Significance
II 期招募中美国NCT06788691A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
II 期招募中美国澳大利亚Czechia法国NCT04419649Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
II 期招募中德国NCT05384691
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。